MNPR 101 Lu-177
Alternative Names: MNPR 101 Lu 177; MNPR 101 lutetium-177Latest Information Update: 26 Aug 2024
At a glance
- Originator Monopar Therapeutics
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer